Houston, TX – According to filings with the U.S. Securities and Exchange Commission, Memgen is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Bob Coates played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Memgen

Memgen is developing new therapies to harness the power of the immune system to potentially cure cancer and to protect people from COVID-19 and other diseases. The Company’s pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in clinical trials and has demonstrated the ability to elicit powerful, antigen-specific immune responses.

To learn more about Memgen, visit http://memgenbio.com/

Contact:
Bob Coates, Chief Executive Officer
858-888-0271
bcoates@memgenbio.com
https://www.linkedin.com/in/bob-coates-3957203/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved